155 related articles for article (PubMed ID: 10192497)
41. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type.
Cuff J; Longacre TA
Am J Surg Pathol; 2012 May; 36(5):688-95. PubMed ID: 22498820
[TBL] [Abstract][Full Text] [Related]
42. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.
Kodama J; Hashimoto I; Seki N; Hongo A; Yoshinouchi M; Okuda H; Kudo T
Anticancer Res; 2001; 21(4B):2983-7. PubMed ID: 11712798
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer.
Sillanpää S; Anttila M; Suhonen K; Hämäläinen K; Turpeenniemi-Hujanen T; Puistola U; Tammi M; Sironen R; Saarikoski S; Kosma VM
Tumour Biol; 2007; 28(5):280-9. PubMed ID: 17962725
[TBL] [Abstract][Full Text] [Related]
44. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
45. Hormonal factors and prognosis in epithelial ovarian cancer: a multivariate analysis.
Blaakaer J; Høgdall CK; Hørding U; Bennett P; Toftager-Larsen K; Daugaard S; Bock J
Eur J Obstet Gynecol Reprod Biol; 1993 Sep; 51(1):21-7. PubMed ID: 8282139
[TBL] [Abstract][Full Text] [Related]
46. Cytologic study of ascites and the endometrium in ovarian carcinoma. Clinical significance.
Hirasawa T; Yasuda M; Muramatsu T; Itoh H; Shinozuka T; Makino T; Tsutsumi Y; Osamura RY
Acta Cytol; 1997; 41(5):1451-5. PubMed ID: 9305383
[TBL] [Abstract][Full Text] [Related]
47. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
[TBL] [Abstract][Full Text] [Related]
48. Clinical significance of ascites in epithelial ovarian cancer.
Huang H; Li YJ; Lan CY; Huang QD; Feng YL; Huang YW; Liu JH
Neoplasma; 2013; 60(5):546-52. PubMed ID: 23790174
[TBL] [Abstract][Full Text] [Related]
49. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
[TBL] [Abstract][Full Text] [Related]
50. Green tea consumption enhances survival of epithelial ovarian cancer.
Zhang M; Lee AH; Binns CW; Xie X
Int J Cancer; 2004 Nov; 112(3):465-9. PubMed ID: 15382073
[TBL] [Abstract][Full Text] [Related]
51. A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.
Al-Badawi IA; Munkarah AR; Tulbah A; Babic II; Al Husaini H; Ahmad S
Int J Gynecol Cancer; 2013 Mar; 23(3):456-60. PubMed ID: 23360812
[TBL] [Abstract][Full Text] [Related]
52. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
[TBL] [Abstract][Full Text] [Related]
53. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
Yigit S; Demir L; Tarhan MO; Cabuk FK; Ellidokuz H; Erten C; Somali I; Dirican A; Cakalagaoglu F
Neoplasma; 2012; 59(5):475-85. PubMed ID: 22668011
[TBL] [Abstract][Full Text] [Related]
54. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
55. Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer.
Scholl SM; Bascou CH; Mosseri V; Olivares R; Magdelenat H; Dorval T; Palangié T; Validire P; Pouillart P; Stanley ER
Br J Cancer; 1994 Feb; 69(2):342-6. PubMed ID: 8297732
[TBL] [Abstract][Full Text] [Related]
56. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
[TBL] [Abstract][Full Text] [Related]
57. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
[TBL] [Abstract][Full Text] [Related]
58. The CD44 receptor is a molecular predictor of survival in ovarian cancer.
Rodríguez-Rodríguez L; Sancho-Torres I; Mesonero C; Gibbon DG; Shih WJ; Zotalis G
Med Oncol; 2003; 20(3):255-63. PubMed ID: 14514975
[TBL] [Abstract][Full Text] [Related]
59. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
Tang L; Zheng M; Xiong Y; Ding H; Liu FY
Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
[TBL] [Abstract][Full Text] [Related]
60. GATA6: a new predictor for prognosis in ovarian cancer.
Shen W; Niu N; Lawson B; Qi L; Zhang J; Li T; Zhang H; Liu J
Hum Pathol; 2019 Apr; 86():163-169. PubMed ID: 30633927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
